ECCO News keeps ECCO Members up-to-date on what is going on within the organisation and reports on IBD activities taking place within Europe. Since Spring 2006, ECCO News has maintained the flow of information between Members of the organisation. 

ECCO News is an important part of the European Crohn’s and Colitis Organisation’s ambition to create a European standard of IBD care and to promote knowledge and research in the field of IBD. 

Editor & Associate Editors

Alessandro Armuzzi
© Alessandro Armuzzi

Nuha Yassin

Ignacio Catalán-Serra
© Ignacio Catalán-Serra

Brigida Barberio
© Brigida Barberio

Spyros Siakavellas
© Spyros Siakavellas

Latest ECCO News Content


New SciCom Members

Janneke van der Woude, SciCom Chair

Janneke van der Woude2Janneke van der Woude

During the ECCO’19 Copenhagen Congress the Scientific Committee cordially welcomed Marc Ferrante as a new member.

Marc Ferrante has been an individual member of ECCO since 2008 and has contributed to several ECCO Activities and Initiatives. He was one of the Y-ECCO Founders and Y-ECCO Chairs. His career in ECCO continued in 2015 with a position on ClinCom, and he subsequently became chair of this committee in 2017. 


Posted in ECCO News, Committee News, SciCom, Volume 14, Issue 2


15th Congress of ECCO - Preliminary Educational Programme

The educational programme of the 15th Congress of ECCO starts prior to the official start of the ECCO Congress and courses take place from February 12-15, 2020. These activities target ECCO’s different interest groups including young gastroenterologists, surgeons, paediatricians, IBD Nurses, dietitians, allied health professionals and scientists.

An overview of these activities can be found below. Please note that courses/workshops may run concurrently. As these educational activities have a limited capacity, we encourage you to register at your earliest convenience.

We look forward to seeing you in Vienna!

Posted in ECCO News, Congress News, ECCO'20, Volume 14, Issue 2


15th Congress of ECCO - Preliminary Scientific Programme

The Scientific Programme of the 15th Congress of ECCO provides attendees the unique opportunity to learn from the world’s leading specialists in the field of Inflammatory Bowel Diseases. Held from Wednesday to Saturday, February 12-15, 2020, the Scientific Programme is structured around basic science, translational medicine and clinical sessions. Additionally, it includes oral presentations of the 40 best abstracts of the Congress. The focus of all sessions is clinical practice founded on science with practical take home messages and, as every year, the congress registration fee includes access to all scientific sessions.

Register now and seize the opportunity to hear current and relevant studies from international experts in IBD!

Posted in ECCO News, Congress News, ECCO'20, Volume 14, Issue 2


ECCO News Associate Editors’ Summary of the 2019 Y-ECCO Abstract Awards and Top 10 DOPs

Nuha Yassin and Ignacio Catalán-Serra, ECCO News Associate Editors

Nuha Yassin v3
Nuha Yassin 
Ignacio Catalán Serra 2019
Ignacio Catalán-Serra
© Ignacio Catalán-Serra

For this second issue of ECCO News in 2019, we would like to continue to review the excellent scientific content presented at the recent annual ECCO´19 annual meeting held in Copenhagen.

We would like to focus our attention this time on the contribution of the Y-ECCO Members, summarizing the five Y-ECCO Abstract Awards for this year, as well as to provide a comprehensive review of the ten awarded digital oral presentations (DOP).

We hope that this representation of high-quality research combining epidemiological, basic and clinical aspects of inflammatory bowel disease is of interest for a wide range of ECCO Members and helps encourage and inspire future innovative work.

Posted in ECCO News, Congress News, ECCO'19, Volume 14, Issue 2


Letter from the ECCO President

Silvio Danese, ECCO President

Silvio Danese
Silvio Danese

Dear ECCO Friends,


One of the ECCO Community’s major aims is to create a network for data sharing that will allow researchers to address clinical issues through collaborative projects. Epidemiology research is one of the tools of value in filling the gaps in our knowledge of Inflammatory Bowel Disease through the collection of large prospective datasets. One highlight of this issue of ECCO News is the summary of the “hot topics” in Epidemiology as they emerged from ECCO ‘19.

As soon as the ECCO’19 Congress in Copenhagen ended, our community immediately started to work towards ECCO’20. A major goal of ECCO is to offer young gastroenterologists, surgeons, paediatricians, IBD Nurses, allied healthcare professionals and scientists an opportunity to improve their knowledge through courses and workshops. In this issue, you will find an overview of the Educational Activities at ECCO’20 and the preliminary Scientific Programme.

Posted in ECCO News, Letters from the ECCO President, Volume 14, Issue 2


ECCO Country Member Profiles: Hungary

Karoly Palatkak and Tamas Molnar, ECCO National Representatives, Hungary



Name of group: Hungarian Colon Section
Number of active members: 200
Number of meetings per year:
President and Secretary: Karoly Palatka (president), Klaudia Farkas (secretary)
National Representatives: Tamas Molnar, Karoly Palatka
Joined ECCO in: 2004
Incidence of IBD in the country (if available): 10/100,000

Posted in ECCO News, ECCO Country Member Profiles, Volume 14, Issue 1


New JCC feature: Podcasts

Tim Raine, JCC Associate Editor

Tim Raine wrc 2016
Tim Raine 

We are excited to announce this new feature to support readers of the Journal of Crohn’s and Colitis (JCC). Since January, key papers accepted for publication in the journal are being accompanied by a short (5-7 minute) audio recording, made available from the Journal homepage.

Posted in ECCO News, ECCO'19, Volume 14, Issue 1


UR-CARE Training Centre at ECCO'19


Report on the main feedback and questions from the delegates


At the 14th Congress of ECCO, the UR-CARE Team received positive feedback from delegates who tried UR-CARE at the UR-CARE Training Centre. Most delegates were very satisfied with the ease of use of the platform and pleasantly surprised that it was free for physicians. Having a standardised platform among the different centres was also very welcomed. People were impressed by the possibility of creating personalised reports of their patients and of having access to a statistical module with the use of desired filters (a timesaving and major asset compared to Access or Excel databases).

Posted in ECCO News, Congress News, UR-CARE News, ECCO'19, Volume 14, Issue 1


Y-ECCO Interview Corner: Tine Jess

Charlotte Hedin, Y-ECCO Member

Charlotte HedinCharlotte Hedin

Our interviewee for this Issue is the current Director of the Center for Clinical Research and Prevention at Bispebjerg and Frederiksberg Hospital in Copenhagen, Denmark. She started her medical training at Herlev University Hospital in Copenhagen, but early in her career the lure of research called and she embarked on a career in epidemiology with a particular focus on IBD and cancer risk. To date she has more than 130 publications listed on PubMed, of which many are highly cited and over 70 are first or last author contributions. She has received many awards for her research and is frequently invited to present her data at international meetings and congresses. Professor Tine Jess, welcome to the Interview Corner.


Posted in ECCO News, Committee News, Y-ECCO, Volume 14, Issue 1


Y-ECCO Literature Review: Aravind Gokul Tamilarasan

Aravind Gokul Tamilarasan

Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in Inflammatory Bowel Disease

Drobne D, Kurent T, Golob S, Švegl P, Rajar P, Hanžel J, Koželj M, Novak G, Smrekar N, Ferkolj I, Štabuc B

Aliment Pharmacol Ther. 2019;49:880–9

Aravind Gokul Tamilarasan
Aravind Gokul Tamilarasan 
© Aravind Gokul Tamilarasan


Since the publication of the landmark SONIC trial in 2010 [1], the use of combination biologic–immunomodulator therapy has been considered best standard practice for patients with Inflammatory Bowel Disease (IBD) who have failed topical therapies or immunomodulators (thiopurines or methotrexate). More recently, real-world data from the PANTS (Personalised anti-TNF therapy in Crohn’s Disease) study demonstrated the benefit of combination therapy (particularly for infliximab) in the form of higher week 54 remission rates and prevention of immunogenicity [2]. Notably, the week 54 remission rates were independent of infliximab trough levels or immunogenicity status, suggesting additional benefits apart from improving the pharmacokinetics of infliximab. This study aimed to provide further real-world data on the effect of combination therapy on clinical and pharmacokinetic outcomes.

Posted in ECCO News, Y-ECCO Literature Reviews, Committee News, Y-ECCO, Volume 14, Issue 1